CN111378745A

CN111378745A - Non-coding RNA-LOC105376991 for diagnosing osteoporosis

Info

Publication number: CN111378745A
Application number: CN202010439295.8A
Authority: CN
Inventors: 杨承刚; 向常娟
Original assignee: Gu'an Bojian Biotechnology Co ltd
Current assignee: Gu'an Bojian Biotechnology Co ltd
Priority date: 2019-05-31
Filing date: 2020-05-22
Publication date: 2020-07-07
Also published as: CN110144396A

Abstract

The invention discloses non-coding RNA-LOC105376991 for diagnosing and treating osteoporosis, and also discloses a product for diagnosing osteoporosis, wherein the product realizes the diagnosis purpose by detecting LOC105376991 in blood. The study of the invention proves that the LOC105376991 level in the blood of the osteoporosis patient is obviously reduced compared with the normal person. According to the correlation between LOC105376991 and osteoporosis, a kit for diagnosing osteoporosis can be prepared, and the kit can be widely applied clinically.

Description

Non-coding RNA-LOC105376991 for diagnosing osteoporosis

Technical Field

The invention belongs to the field of biomedicine, and relates to non-coding RNA for diagnosing osteoporosis, wherein the non-coding RNA is LOC 105376991.

Background

The incidence of osteoporosis (osteoporotis in men) in men is much lower than that in postmenopausal women, so that importance on osteoporosis in men has been far less than that in women. Recent research results show that men in the young age achieve higher peak bone mass than women, and the initial time of bone mass loss is obviously later than women, but both men and women have a bone loss process in phase with the age, namely senile osteoporosis (type II). Male osteoporosis shares many similarities with female osteoporosis, but there are still significant gender differences in etiology, pathology, and color pathology. Men over age 65 have a common occurrence of osteoporosis of varying degrees, with a severe complication of fracture.

In the United states, the incidence rate of hip fracture in men older than 65 years old is 4-5 per mill, and the incidence rate in women of corresponding ages is 8-10 per mill. Hip fractures occur at a rate of 1: 2 for men and women in northern europe, and relatively low in both sexes and other areas. Of all patients with hip fractures worldwide, about 30% are men, 51 million in 1990, and it is expected that the number of male hip fractures will increase to 116 million by 2025, and this rising trend will be more prominent in asia.

Cooper reported that men over age 50 had a lifetime risk of hip, vertebral and forearm fractures of 13.1% and women 39.7%. Neill reports 20% prevalence of vertebral fractures in 19 European countries 36 central 15570 cases of men 50-79 years old. According to the xushangzhong report about the prevalence rate of osteoporosis of male in China, the prevalence rate of male over 60 years old is 13.9%; wuqing in beijing area reported 13.4% (lumbar vertebrae); shenhuilan is reported to be 23.8% (lumbar).

Osteoporotic fractures cause loss of living ability and life risk to patients, and Poor reports that mortality and morbidity of fractures are higher in men than in women.

Like female osteoporosis, normal x-rays remain an essential means of diagnosing male osteoporosis and related fractures. The first manifestation is a decrease in bone density of the spine and pelvis. The cortical bone of the vertebral body becomes thin, trabecular bone in transverse motion is reduced or disappears, trabecular bone in longitudinal motion is relatively obvious, and the structure in the vertebral body disappears when the trabecular bone in longitudinal motion is serious; the vertebral body becomes flat, the upper and lower edges are concave, the intervertebral space is widened, the vertebral body is biconcave, and is compressed into wedge shape due to slight trauma. The thinning, reduction in the number of trabeculae, thinning of the cortex of the bone and the occurrence of delamination are observed on long bones. In severe cases, scattered and several mm-sized spot-like bright areas appear on the basis of diffuse bone density reduction, and the boundary is clear or fuzzy, so that bone destruction is easily misdiagnosed. However, the X-ray plain film has low sensitivity and accuracy for diagnosing osteoporosis, and is not helpful for early diagnosis of osteoporosis. Therefore, it is highly desirable to develop a method for diagnosing osteoporosis in an early stage of osteoporosis.

Disclosure of Invention

The technical problem to be solved by the invention is to provide a long-chain non-coding RNA marker related to the diagnosis of male osteoporosis aiming at the current situation of the prior art.

Another technical problem to be solved by the present invention is to provide a method for detecting the lncRNA marker, which is not directly used for diagnosis and treatment of diseases.

The invention also provides an application of the lncRNA marker in preparing a product for diagnosing male osteoporosis.

In order to solve the technical problems, the invention adopts the following technical scheme:

in one aspect of the invention, an isolated long non-coding RNA associated with diagnosis of male osteoporosis is LOC 105376991.

In another preferred embodiment, the LncRNA is isolated from blood and/or tissue of a human or non-human mammal.

In another preferred embodiment, the blood is plasma and/or serum.

In another preferred embodiment, the blood does not include blood cells.

In another preferred embodiment, the non-human mammal is a mouse, rat, rabbit, pig, cow, sheep, etc.

In another preferred embodiment, the LncRNA is isolated from human blood.

In a second aspect of the invention, there is provided an isolated polynucleotide capable of being transcribed by a human cell into a long non-coding RNA according to the first aspect of the invention.

In a third aspect of the invention, there is provided a vector comprising a polynucleotide according to the second aspect of the invention, or expressing a long non-coding RNA according to the first aspect of the invention.

In a fourth aspect of the present invention, there is provided a reagent capable of detecting the expression level of the long non-coding RNA of the first aspect of the present invention.

Further, the reagent comprises a PCR amplification primer used for detecting the expression quantity of the long-chain non-coding RNA by using SYBR Green, a TaqMan probe, a molecular beacon, a double-hybridization probe or a composite probe.

In a specific embodiment of the invention, the primer sequences are shown as SEQ ID NO.1 and SEQ ID NO. 2.

In a fifth aspect of the present invention, there is provided a chip for diagnosing osteoporosis, the chip comprising a solid support and oligonucleotide probes immobilized on the solid support in an ordered manner, wherein the oligonucleotide probes specifically correspond to the long non-coding RNA of the first aspect of the present invention.

In a sixth aspect of the invention, there is provided the use of the chip of the fifth aspect of the invention for the preparation of a kit for the diagnosis of osteoporosis in men.

In a seventh aspect of the invention, there is provided a kit comprising a long non-coding RNA according to the first aspect of the invention or a reagent according to the fourth aspect of the invention, or a chip according to the fifth aspect of the invention.

Further, the kit of the present invention may further comprise the following components required for RT-PCR reaction: PCR buffer, 10mM dNTPs, Hot start Taq enzyme, ddH₂O。

Furthermore, the kit of the invention can also comprise cDNA obtained by reverse transcription of long-chain non-coding RNA, and the cDNA is used as a positive template for detecting the feasibility of the primer.

In the eighth aspect of the invention, the use of the long-chain non-coding RNA of the first aspect of the invention or the reagent of the fourth aspect of the invention for preparing a chip or a kit for diagnosing male osteoporosis is provided.

The invention provides the use of a long non-coding RNA according to the first aspect of the invention in the manufacture of a medicament for the treatment of osteoporosis.

Further, the medicament includes a substance that promotes expression of the long non-coding RNA.

The medicament also comprises a pharmaceutically acceptable carrier. The effective components, substances promoting the expression of the biomarkers and pharmaceutically acceptable carriers are prepared into the medicament by the conventional pharmaceutical technology.

The substance promoting the expression of the long non-coding RNA of the present invention is not limited as long as it can promote or enhance the expression of the long non-coding RNA or a substance involved in the upstream or downstream pathway of the long non-coding RNA and is effective for treating osteoporosis.

The substance promoting the expression of the long-chain non-coding RNA can promote the proliferation of osteoblasts related to osteoporosis and the differentiation of osteoblasts from the functional point of view.

The types of substances that promote the expression of the long non-coding RNA can include nucleic acids, carbohydrates, lipids, small compounds, polypeptides, proteins, polysaccharides.

Specifically, the substance promoting the expression of the long-chain non-coding RNA comprises the long-chain non-coding RNA, an overexpression vector or host cell containing the long-chain non-coding RNA, a promoting miRNA, a promoting transcription regulatory factor, or a promoting targeting small molecule compound.

The substance for promoting the expression of the long-chain non-coding RNA can be used for supplementing the deletion or deficiency of the endogenous long-chain non-coding RNA and treating osteoporosis caused by the deficiency of the long-chain non-coding RNA by improving the expression of the long-chain non-coding RNA.

The present invention also provides a pharmaceutical composition for treating osteoporosis, comprising the above-mentioned substance promoting the expression of the long-chain non-coding RNA.

The pharmaceutical compositions of the present invention also include a pharmaceutically acceptable carrier, such carriers including (but not limited to): diluents, excipients such as water and the like, fillers such as starch, sucrose and the like; binders such as cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone; humectants such as glycerol; disintegrating agents such as agar, calcium carbonate and sodium bicarbonate; an absorption enhancer quaternary ammonium compound; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite; lubricants such as talc, calcium and magnesium stearate, polyethylene glycol, and the like.

The pharmaceutical composition can also be used together with other medicines for treating osteoporosis, and the combination of a plurality of medicines can greatly improve the success rate of treatment.

The method of using the kit of the present invention is described below:

(1) extracting LncRNA of the first aspect of the present invention from a sample from a test subject;

(2) and (3) detecting the content of LncRNA, comparing the result with the content of LncRNA in the normal population, and if the content of LncRNA in the sample L1 is obviously lower than the content of LncRNA in the normal population L0, indicating that the detected object has osteoporosis or has high probability of osteoporosis.

In another preferred example, said significantly lower is defined as L0/L1 ≧ 1.5, preferably ≧ 2.0, more preferably ≧ 5.

In another preferred example, the test subject includes a normal male not suffering from osteoporosis, a male patient suspected of suffering from osteoporosis, or a male patient diagnosed with osteoporosis.

In the context of the present invention, "diagnosing osteoporosis" includes determining whether a subject has suffered from osteoporosis, determining whether a subject is at risk of suffering from osteoporosis.

As used herein, the terms "LncRNA", "Long non-coding RNA", "Long non-coding RNA" and "Long non-coding RNA" are synonymous and used interchangeably and refer to a fragment of RNA transcribed by RNA polymerase II that does not encode a protein and is generally greater than 200bp in length.

As used herein, the term "isolated" refers to a substance that is separated from its original environment (which, if it is a natural substance, is the natural environment). If the polynucleotide or polypeptide in its native state in a living cell is not isolated or purified, the same polynucleotide or polypeptide is isolated or purified if it is separated from other substances coexisting in its native state.

Of course, LncRNA or a detection reagent thereof (e.g., an oligonucleotide capable of binding to LncRNA as a probe and further prepared as a chip) can be chemically synthesized according to the relative LncRNA sequence or a complementary sequence thereof in the database according to a conventional technique, or a cDNA sequence thereof can be used to prepare an expression vector and transcribe it into LncRNA.

Polynucleotide constructs

According to the human LncRNA sequence provided by the present invention, a polynucleotide construct that can be processed into LncRNA that can affect the expression of the corresponding mRNA after being introduced, i.e., the polynucleotide construct can up-regulate the amount of the corresponding LncRNA in vivo, can be designed. Accordingly, the present invention provides an isolated polynucleotide (construct) that can be transcribed into LncRNA by human cells.

Typically, the polynucleotide construct is located on an expression vector. Accordingly, the present invention also includes a vector comprising said LncRNA, or said polynucleotide construct. The expression vector usually further contains a promoter, an origin of replication, and/or a marker gene.

Methods well known to those skilled in the art can be used to construct the expression vectors required by the present invention. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombinant techniques, and the like. The expression vector preferably comprises one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as kanamycin, gentamicin, hygromycin, ampicillin resistance.

Chip and method for manufacturing the same

The LncRNA expression profiling chip usually contains up to several hundred probes, covers various RNAs, and utilizes the principle of DNA double-strand homologous complementation to detect the content of various RNAs in a sample at the whole genome level. Therefore, the transcription level of the RNA in the whole genome range in the sample to be tested can be detected at the same time.

By utilizing the LncRNA sequence, a corresponding LncRNA detection chip can be prepared, and the expression profile and the regulation mode of the LncRNA can be further researched.

Specifically, suitable probes can be designed based on the LncRNA of the present invention, and immobilized on a solid support to form an "oligonucleotide array". By "oligonucleotide array" is meant an array having addressable locations (i.e., locations characterized by distinct, accessible addresses), each addressable location containing a characteristic oligonucleotide attached thereto. The oligonucleotide array may be divided into a plurality of subarrays as desired.

The solid phase carrier can adopt various common materials in the field of gene chips, such as but not limited to nylon membranes, glass slides or silicon wafers modified by active groups (such as aldehyde groups, amino groups and the like), unmodified glass slides, plastic sheets and the like.

The LncRNA chip can be prepared by a conventional method for manufacturing a biochip known in the art. For example, if a modified glass slide or silicon wafer is used as the solid support, and the 5' end of the probe contains a poly-dT string modified with an amino group, the oligonucleotide probe can be prepared into a solution, and then spotted on the modified glass slide or silicon wafer by using a spotting instrument, arranged into a predetermined sequence or array, and then fixed by standing overnight, so as to obtain the miRNA chip of the invention. If the nucleic acid does not contain amino modifications, the preparation can also be referred to: the "Gene diagnostic technique-non-Radioactive operation Manual" edited by Wangshen five; l.l.e risi, v.r.i.er, p.o.brown.expanding the metabolic and genetic control of genetic compression a genetic scale, science, 1997; 278:680 and maliren, jiang china main edition biochip, beijing: chemical industry Press, 2000, 1-130.

Reagent kit

The kit of the present invention can be used for detecting the expression of the LncRNA in blood. Preferably, the kit further comprises a marker for marking the RNA sample and a substrate corresponding to the marker. Preferably, LncRNA contained in the kit of the present invention can also be used for performing a positive control. In addition, the kit may further include various reagents required for RNA extraction, PCR, hybridization, color development, and the like, including but not limited to: an extraction solution, an amplification solution, a hybridization solution, an enzyme, a control solution, a color development solution, a washing solution, an antibody, and the like. In addition, the kit can also comprise an instruction book and/or chip image analysis software.

Drawings

FIG. 1 shows a statistical chart for detecting the differential expression of LOC105376991 by QPCR;

FIG. 2 is a graph showing the results of alkaline phosphatase activity detection using the alkaline phosphatase assay kit.

Detailed Description

The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Cold Spring harbor laboratory Press,1989), or according to the manufacturer's recommendations.

Example 1 screening for differentially expressed molecules

1. Case collection

Selecting 5 cases of senile male osteoporosis patients, with age of 62-79 years; the osteoporosis diagnosis refers to the standard set by osteoporosis committee of the Chinese senile society, namely, the osteoporosis is determined as the result that the density value of bones at the same part is lower than the peak value of the local area by two standard differences. Healthy elderly men 6 (healthy control group) were selected at the same time, age 61-78 years. The selected subjects are excluded from diseases affecting bone metabolism, such as diabetes, primary hyperparathyroidism, hyperthyroidism, hypercortisolism, liver and kidney dysfunction, alcoholism, malnutrition, rheumatoid arthritis, and the like; androgens, calcitonin, calcium rich agents, bisphosphonates and other drugs affecting bone metabolism are not used for half a year. The age, height, body mass, diet and daily exercise of the two groups are comparable.

2. Blood Total RNA extraction

Total RNA was extracted using an RNA extraction kit from Promega corporation. The method comprises the following specific steps:

1) taking 1ml of whole blood collected in a test tube treated by heparin or EDTA, and putting the whole blood into a sterile centrifuge tube;

2) centrifuging at 3000rpm for 5min, and carefully sucking the supernatant from the top of the sample;

3) adding 1ml of blood cell lysate, carefully sucking and placing for 4-5 times, re-suspending the precipitate, and centrifuging at 3000rpm for 5 min;

4) repeating the step 3 twice;

5) avoid cell pellet, carefully aspirate almost all supernatant, retain only 100 μ l supernatant; confirming that BME has been added to the RNA lysate, then adding 175. mu.l of RNA lysate to the cells, pipetting, resuspending and lysing the cells;

6) adding 350 μ l of RNA diluent, mixing by inversion for 3-4 times, centrifuging at 13000g for 10min at room temperature, and transferring clear lysate to a sterile centrifuge tube;

7) adding 200 μ l 95% ethanol into the clarified lysate, and mixing by pipetting for 3-4 times; transferring the mixture into a centrifugal column assembly, and centrifuging for 1min at 13000 g;

8) taking down the centrifugal column from the centrifugal column assembly body, discarding the liquid in the collecting pipe, putting the centrifugal column back on the collecting pipe, adding 600 mu l of RNA washing liquid into the centrifugal column assembly body, and centrifuging for 1min at 13000 g;

9) discarding the liquid from the collection tube, loading the column back onto the collection tube, and adding 50 μ l of freshly prepared DNase incubation mixture directly onto the membrane inside the column;

10) incubating at room temperature for 15min, adding 200 μ l DNase termination buffer solution into the centrifugal column, and centrifuging at 13000g for 1 min;

11) adding 600 μ l RNA washing solution, 13000g, centrifuging for 1 min;

12) emptying the collection tube, adding 250 μ l of RNA washing solution (added with ethanol) into the centrifugal column, and centrifuging at high speed for 2 min;

13) transferring the centrifugal column from the collecting tube to an elution tube, adding 100. mu.l of nuclease-free water to the membrane, placing the assembly of the centrifugal column into a centrifuge with the cap of the elution tube facing outwards, centrifuging at 13000g for 1min, discarding the centrifugal column, capping the elution tube with RNA, and storing at-70 ℃.

3. RNA quality detection

Total RNA concentration and purity were determined using a NanoDropND-1000 type UV spectrophotometer.

4. Total RNA integrity determination RNA integrity was checked by electrophoresis on 1% formaldehyde-denatured agarose gel, and inspection under UV transmitted light.

5. Agilent2100 measures RIN values.

lncRNA sequencing requirements: sample requirement: not less than 200 ng; sample concentration: c is more than or equal to 20 ng/mu L; purity of the sample: RIN is more than or equal to 7.0, and 28S/18S is more than or equal to 1.0.

6. Removal of rRNA

A part (> 24%) of long non-coding RNA in cells is short of a traditional poly A tail, so that more comprehensive lncRNA information can be obtained by constructing a library in a way of removing rRNA.

7. Fragmented RNA

The Illumina platform is used for sequencing short sequence fragments, mRNA and lncRNA obtained by removing rRNA are complete RNA sequences, the average length can reach several kb, and random interruption is needed. The RNA can be randomly fragmented into small fragments of about 200bp by using metal ions.

8. Reverse Synthesis of cDNA

When double-strand synthesis is performed by reverse-transcribing a single-strand cDNA using mRNA as a template with a random primer by reverse transcriptase, dUTP is used instead of dTTP in dNTPs reagents so that the base in the second strand of the cDNA contains A/U/C/G.

9. Connection adapter

The double-stranded cDNA structure is sticky-ended, and is made blunt-ended by adding End Repair Mix, followed by an A base at the 3' End for ligation to a Y-shaped adaptor.

10. UNG enzyme digestion of cDNA double strand

Before PCR amplification, the second strand of cDNA was digested with UNG enzyme, so that only the first strand of cDNA was contained in the library.

11. Sequencing on an Illumina Hiseq2500 machine

Illumina Hiseq2500 sequencing platform, 2 × 150bp sequencing was performed.

12. Bioinformatics analysis

The procedure of analysis of raw data after obtaining sequencing data is as follows:

(1) carrying out trim on 5 'and 3' sections of reads by using cutadapt, wherein bases with the mass of less than 20 are removed from trim, and more than 10% of reads with N are deleted;

(2) tophat aligns to the reference genome. The reference genome version used was grch38.p7, fasta and gff files downloaded from NCBI;

(3) the expression quantity of the lncRNA is quantified and outputted in a standardized way by cuffquant;

(4) cuffdiff compares the difference in lncRNA expression between the control and disease groups.

13. Results

Significantly different lncRNA screening conditions: FDR < 0.01. The following results were obtained using the above standard screen: compared to healthy controls, the differential expression of LncRNA in blood of osteoporosis patients was 359, with up-regulation of 214 and down-regulation of 145.

Example 2 validation of Large samples the differentially expressed LncRNA selected

1. Sample collection

32 osteoporosis patients and 30 male healthy controls were collected as in example 1.

2. Extraction of blood Total RNA

The procedure is as in example 1.

3. Validation at the RNA level

(1) Reverse transcription: based on the measured RNA concentrations, 1000ng of RNA per sample was quantified for reverse transcription. Using DDR037A reverse transcription kit from Dalibao organisms, 20. mu.l of the system (see Table 1), 200ul of the enzyme-removed EP tube was added, centrifuged and placed in a PCR apparatus under temperature conditions set as: 15min at 37 ℃ and 5sec at 85 ℃. After completion, the cDNA was diluted 10-fold and stored at-20 ℃ for further use.

TABLE 1 reverse transcription System

(2) Real-time quantitative PCR

Shanghai biological synthesis primer.

LOC105376991

An upstream primer: 5'-CCTAAGATACAACACAACA-3' (SEQ ID NO. 1);

a downstream primer: 5'-CAGATTCTCAAGCAACAT-3' (SEQ ID NO. 2).

β-actin

An upstream primer: 5'-CGCGAGAAGATGCCCAGATC-3' (SEQ ID NO. 3);

a downstream primer: 5'-TCACCGGAGTCCATCACGA-3' (SEQ ID NO. 4).

The detection was carried out by using a real-time quantitative PCR instrument (AB StepOne Plus) of ABI, USA, SYBRGreen dye incorporation method of Toyo Boseki (TOYOBO), and the cDNA obtained by reverse transcription was diluted ten-fold and 20. mu.l was used as a reaction system (see Table 2). The amplification conditions were: pre-denaturation at 95 ℃ for 60sec, followed by denaturation at 95 ℃ for 15sec and elongation at 51 ℃ for 60sec for 40 cycles to obtain Ct values of the target gene and the internal reference.

TABLE 2PCR System

Reagent	Amount of the composition used
		cDNA	2μl
SYBR green	10μl
		Dye	0.4μl
Upstream primer (10. mu.M)	1μl
		Downstream primer (10. mu.M)	1μl
Sterilization double distilled water	To 20. mu.l

The result is obtained by a relative quantitative method using formula 2^-△△ctAnd (4) calculating.

4. Results

The results show that the LOC105376991 level in the blood of 31 of 32 male osteoporosis patients was significantly lower than the healthy control compared to the average level of 30 healthy men. Statistical results as shown in figure 1, LOC105376991 levels were significantly reduced in the blood of male osteoporosis patients compared to healthy males, with the differences being statistically significant (P < 0.05).

Example 3 Effect of LOC105376991 expression on osteoblast proliferation and differentiation

First, overexpression Pre-experiment

1. Grouping experiments:

the experiments were divided into 2 groups: the empty vector control group (pcDNA3.1) and the pcDNA3.1-LOC105376991 group.

2. Construction of LOC105376991 expression vector

An amplification primer is designed according to the LOC105376991cDNA sequence, the full-length LOC105376991cDNA is amplified from a cDNA library of adult fetal brain (Clontech company, cat # 638831), the cDNA sequence is inserted into a eukaryotic cell expression vector pcDNA3.1, and the obtained recombinant vector pcDNA3.1-LOC105376991 is connected for subsequent experiments.

3. Cell culture

Human osteoblasts hFOB1.19 were plated on 5% CO₂Culturing in 34 deg.C incubator with DMEM (high sugar)/F12 complete medium (DMEM (high sugar)/F12 supplemented with 10% fetal calf serum and finalG418 at a concentration of 0.3%).

4. Cell transfection

Culturing osteoblasts in vitro, inoculating the osteoblasts in a 6-well plate 24h before transfection, adding DMEM/F12 medium, adhering to the wall overnight, and performing transfection when the cells are 80-90% confluent. Before transfection, DMEM/F12 medium without serum was used instead. The plasmid was diluted with 250. mu.l DMEM/F12 and gently pipetted 3-5 times and mixed well. The transfection reagent was mixed by gentle inversion, 5. mu.l of liposome 2000 was diluted with 250. mu.l of DMEM/F12 medium, mixed by gentle pipetting 3-5 times, and allowed to stand at room temperature for 5 min. Mixing transfection reagent and plasmid diluent, gently blowing and sucking for 3-5 times, mixing, and standing at room temperature for 20 min. The transfection complex was added to a 6-well cell plate and mixed well by gently shaking the cell plate back and forth. The cell plate was incubated at 34 ℃ with 5% CO₂Culturing in an incubator. The transfection time was 6h with serum-containing DMEM/F12 medium.

5. Detection of overexpression vector by QPCR (quantitative polymerase chain reaction) experiment

The total RNA of the cells is extracted by using a conventional method, and then reverse transcription and QPCR detection are carried out, and the results show that: the pcDNA3.1-LOC105376991 constructed by the invention can improve the expression of LOC105376991 by about 8 times, and can be further used for carrying out subsequent experiments.

Second, cell proliferation assay

Osteoblasts were seeded in 96-well cell culture plates and transfected as described above, and 48h after cell culture³H-TdR (0.5. mu. Ci/well) was cultured for a further 16H, cells were harvested after trypsinization, and the cpm value of each well sample was determined on a scintillation counter.

As a result: the cell cpm value of the empty vector control group (pcDNA3.1) was 1079.07 + -60.89, the cell cpm value of the pcDNA3.1-LOC105376991 group was 2607.01 + -139.05, and the difference between the two groups was statistically significant (P ═ 0.001465). The above results indicate that promoting expression of LOC105376991 can promote osteoblast proliferation.

Third, cell differentiation experiment

The 6-well plates were seeded with hFOB1.19 cells. Plasmid transfection was performed as described above, and the cell culture fluid was aspirated 24h after transfection, centrifuged at 2500r/min for 10min, and the supernatant was assayed using an alkaline phosphatase assay kit.

Alkaline phosphatase ═ [ (measured absorbance value-blank absorbance value)/(standard absorbance value-blank absorbance value) ] × phenol standard concentration × 100mL × sample dilution factor before measurement.

The absorbance (A value) of each well was measured at a wavelength of 520nm by a microplate reader, and the relative ALP activity was calculated from the measured A value.

The results are shown in FIG. 2: the supernatant phosphatase activity (2.258 ± 0.106) of pcDNA3.1-LOC105376991 group was significantly increased compared to the empty vector control group (0.628 ± 0.014), and the difference was statistically significant (P ═ 0.001542). It is indicated that promoting expression of LOC105376991 can promote osteoblast differentiation.

The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.

Sequence listing

<110> Gu' an Bo Jian Biotechnology Ltd

<120> non-coding RNA-LOC105376991 for diagnosis and treatment of osteoporosis

<150>201910473211.X

<151>2019-05-31

<160>4

<170>SIPOSequenceListing 1.0

<210>1

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>1

cctaagatac aacacaaca 19

<210>2

<211>18

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>2

cagattctca agcaacat 18

<210>3

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>3

cgcgagaaga tgcccagatc 20

<210>4

<211>19

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>4

tcaccggagt ccatcacga 19

Claims

1. An isolated long non-coding RNA, wherein said long non-coding RNA is LOC 105376991.

2. An isolated polynucleotide capable of being transcribed by a human cell into the long non-coding RNA of claim 1.

3. A vector comprising the polynucleotide of claim 2 or expressing the long non-coding RNA of claim 1.

4. A reagent for detecting the expression level of the long non-coding RNA according to claim 1.

5. A chip for diagnosing osteoporosis, comprising a solid support and oligonucleotide probes immobilized on the solid support in an ordered manner, wherein the oligonucleotide probes specifically correspond to the long non-coding RNA of claim 1.

6. Use of the chip of claim 5 for the preparation of a kit for the diagnosis of osteoporosis.

7. A kit comprising the long non-coding RNA of claim 1 or the reagent of claim 4, or the chip of claim 5.

8. Use of the long non-coding RNA of claim 1, or the reagent of claim 4, for the preparation of a chip or a kit for the diagnosis of osteoporosis; preferably, the reagent comprises a PCR amplification primer used for detecting the expression quantity of the long-chain non-coding RNA by using SYBR Green, a TaqMan probe, a molecular beacon, a double-hybridization probe or a composite probe; more preferably, the primer sequences are shown as SEQ ID NO.1 and SEQ ID NO. 2.

9. Use of the long non-coding RNA of claim 1 for the manufacture of a medicament for the treatment of osteoporosis; preferably, the medicament comprises a substance that promotes the expression of the long non-coding RNA; more preferably, the agent is an overexpression vector for the long non-coding RNA.

10. A pharmaceutical composition for treating osteoporosis, said pharmaceutical composition comprising a substance that promotes the expression of said long non-coding RNA; preferably, the agent is an overexpression vector for the long non-coding RNA.